Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial

Autor: Aghajanian, Carol, Swisher, Elizabeth M., Okamoto, Aikou, Steffensen, Karina Dahl, Bookman, Michael A., Fleming, Gini F., Friedlander, Michael, Moore, Kathleen N., Tewari, Krishnansu S., O'Malley, David M., Chan, John K., Ratajczak, Christine, Hashiba, Hideyuki, Wu, Meijing, Dinh, Minh H., Coleman, Robert L.

Publikováno v: Gynecologic oncology, vol 164, iss 2
Aghajanian, C, Swisher, E M, Okamoto, A, Steffensen, K D, Bookman, M A, Fleming, G F, Friedlander, M, Moore, K N, Tewari, K S, O'Malley, D M, Chan, J K, Ratajczak, C, Hashiba, H, Wu, M, Dinh, M H & Coleman, R L 2022, ' Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer : an ancillary data analysis of the VELIA trial ', Gynecologic Oncology, vol. 164, no. 2, pp. 278-287 . https://doi.org/10.1016/j.ygyno.2021.12.012

ObjectiveIn the Phase 3 VELIA trial (NCT02470585), veliparib added to carboplatin plus paclitaxel concomitantly and as maintenance for women with newly-diagnosed advanced ovarian cancer significantly improved progression-free survival (PFS) versus ch

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb73cea4798f3dd80fc5c9793e913e0f
https://doi.org/10.1016/j.ygyno.2021.12.012

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.